IMCLONE IND FOR BEC-2 ANTI-IDIOTYPE ANTIBODY MELANOMA TREATMENT
Executive Summary
IMCLONE IND FOR BEC-2 ANTI-IDIOTYPE ANTIBODY MELANOMA TREATMENT was filed in September and the seven-year-old firm expects to begin its first clinical trials before the end of the year, ImClone said in an Oct. 1 preliminary prospectus for an initial public offering. Phase I trials for the treatment of malignant melanoma will be conducted by the New York City-based company's collaborators at Memorial Sloan-Kettering Cancer Center. , BEC-2 is designed to stimulate the immune system to "prevent or delay the onset of recurrent primary tumors or metastatic disease" after surgical removal of a tumor. ImClone signed up German ImCone Signed up german firm E. Merck as a licensing partner for BEC-2 in December 1990. E. Merck paid an initial fee of $ 3.5 mil. for European rights and agreed to additional research support and milestone payments. ImClone intends to retain U.S. rights to manufacture and market BEC-2. Another start-up firm, IDEC Pharmaceuticals, recently completed Phase I trials on its anti-id for melanoma, I Mel-I IMel-1 ("The Pink Sheet" July july 8, T&G- 6). The three other principal products under development by ImClone are a totipotent stem ceel cell growth factor (T-SCF) as an adjunct to chemotherapy, radiation therapy and bone marrow transplants; a recombinant molecular variant of interleukin-6; and an interleukin-1 inhibitor. ImClone expects Erbamont to initiate clinicl clinical trials on the IL-6 variant by the end of 1992. A May 1989 licensing pact gives Erbamont N.V. exclusive worldwide rights to manufacture and market hematopoietic hematopooietic growt factors developed as part of the agreement. Erbamont has provided $ 2.6 mil. in research fees for IL-6 to date and is responsible for pre-clinical and clinical studies as well as obtaining regulatory and marketing approval. Although Immunex/Hoechst's granulocyte macrophage-colony stimulating factor and Amgen's G-CSF have been approved for the treatment of neutropenia, ImClone notes that it is "not aware of any effective drug therapy for thrombocytopenia [the reduction of platelets resulting in susceptibility to bleeding], a condition which affects a high proportion of patients" undergoing cancer therapy. The 2 mil. share offering for an estimated $ 14 per share should fund operations through 1993, ImClone said. Approximately $ 15 mil. of the anticipated $ 25.5 mil. net proceeds from a successful offering is intended for R&D. About $ 2 mil. will be used to retire debt, with the balance of the proceeds going toward general corporate expenses, including the possible construction of a clinical-scale manufacturing facility. As of June 30, ImClone had an accumulated deficit of around $ 33 mil. The estimated proceeds from the initial public offering would match the $ 25 mil. ImClone previously netted through private placements. The firm has received an additional $ 7.1 mil. in R&D support and licensing fees totaling $ 5.7 mil. American Cyanamid terminated a 1989 licensing agreement for wound healing growth factors in September after providing $ 1 mil. in research support. An earlier Cyanamid/ImClone pact focusing on vaccines has resulted in ImClone identifying vaccine candidates for gonorrhea and herpes simplex. Cyanamid is responsible for conducting preclinical and clinical trials; ImClone believes clinical trials for the gonorrhea vaccine might begin in 1992. ImClone was founded in 1984 by two brothers who were previously in academic posts: President and CEO Samuel Waksal, PhD, and Exec VP and Chief Operating Officer Harlan Waksal, MD. The Waksals will control 31% of ImClone stock post-offering, while Erbamont and American Cyanamid will have beneficial stakes of 8% and 6% stake, respectively.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth